Braveheart Bio
Director, Controller
San Francisco, CA or Remote or Hybrid · Director
Sponsorship not specifiedDetected 4 days ago
AccountingForecastingBudgetingFP&ATaxLeadershipInternal AuditAccounts PayableNetSuite
About the role
- Reporting to the VP of Finance, this individual will own day-to-day accounting operations and related internal controls, including month-end, quarter-end, and year-end close processes, as well as lead necessary system implementations to support the Company's continued growth.
Responsibilities
- Develop and own the clinical trial accrual process including reviewing clinical contracts, CRO reports, patient costs, site costs, and invoices for timely and proper accrual. Liaise directly with clinical vendors to ensure completeness and accuracy.
- Manage accounts payable and cash disbursements to ensure timely and accurate payments to our vendors.
- Coordinate with FP&A to support their budgeting and forecasting needs and their creation of budget vs actuals, including ensuring timely and accurate reporting of actuals.
- Develop and maintain accounting policies, procedures, and internal controls that can scale through an IPO and beyond.
- Evaluate, implement, and optimize financial systems, including Netsuite and a new payrol l system.
- The Director, Controller is an experienced leader that will build and run the financial infrastructure of our fast-moving clinical-stage biotechnology company.
- This is a hands-on role that will collaborate with various internal and external partners, including non-finance operating teams.
Compensation
- Own the monthly, quarterly, and annual close proces s to ensure accurate financial statements on a timeline that meets internal and external reporting deadlines.
Company info
- Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart's goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
- With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
- The role:
- The Director, Controller is an experienced leader that will build and run the financial infrastructure of our fast-moving clinical-stage biotechnology company. Reporting to the VP of Finance, this individual will own day-to-day accounting operations and related internal controls, including month-end, quarter-end, and year-end close processes, as well as lead necessary system implementations to support the Company's continued growth. This is a hands-on role that will collaborate with various internal and external partners, including non-finance operating teams.
- Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
- Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
- Braveheart's goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
Apply directly at Braveheart Bio →Create a free account for alerts like thisView Braveheart Bio immigration profile
This listing is sourced directly from Braveheart Bio's careers page and normalized into a canonical job model.